Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2179)

ANNOUNCEMENT IN RELATION TO COMPLETION OF INDUSTRIAL AND COMMERCIAL REGISTRATION FOR REGISTERED CAPITAL ALTERATION, RENEWAL OF BUSINESS LICENSE AND AMENDMENTS TO ARTICLES OF ASSOCIATION

References are made to the announcements (the "**Announcements**") of Jiangsu Recbio Technology Co., Ltd. (the "**Company**") dated November 11, 2024, December 24, 2024, January 9, 2025, February 27, 2025, July 23, 2025 and October 16, 2025, respectively, and the notice and circular (the "**Circular**") of the 2024 first extraordinary general meeting, both dated December 5, 2024, in relation to, among other things, details of the proposed issuance of domestic shares to target subscribers and the proposed authorization for the Board of Directors and its authorized persons to handle matters relating to the issuance of domestic shares to target subscribers. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

As stated in the Announcements, the Company has received the Approval for the Registration of Issuance of Shares by Jiangsu Recbio Technology Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2025] No. 1506) from China Securities Regulatory Commission, and the proceeds from the issuance have been fully paid. Upon completion of the issuance, the registered capital of the Company will change from RMB482,963,000 to RMB626,075,702.

Recently, the Company has registered alteration of registered capital with industrial and commercial authority with respect to the issuance and obtained a renewed business license from Taizhou Administration for Market Regulation. The industrial and commercial filing has been completed in respect of the amended Articles of Association. Details of the amendments to the Articles of Association are set out as follows:

Article No.	**Before amendment**	**After amendment**
Article 6	The registered capital of the Company is RMB~~482,963,000~~.	The registered capital of the Company is RMB**626,075,702**.
Article 20	The Company has a total of ~~482,963,000~~ shares, including ~~154,824,311~~ domestic shares, accounting for ~~32.06~~% of the total share capital of the Company; and 328,138,689 foreign shares, accounting for ~~67.94~~% of the total share capital of the Company; and 316,138,689 H shares, accounting for ~~65.46~~% of the total share capital of the Company; and the foregoing shares are all ordinary shares.	The Company has a total of **626,075,702** shares, including **297,937,013** domestic shares, accounting for **47.59**% of the total share capital of the Company; and 328,138,689 foreign shares, accounting for **52.41**% of the total share capital of the Company; and 316,138,689 H shares, accounting for **50.50**% of the total share capital of the Company; and the foregoing shares are all ordinary shares.

According to the Circular, the 2024 first extraordinary general meeting authorized the Board of Directors and its authorized person to deal with matters relating to the issuance of domestic shares to target subscribers, including making corresponding amendments to the provisions in the Articles of Association in respect of the registered capital and shareholding structure of the Company. These amendments to the Articles of Association do not need to be submitted to the general meeting for consideration.

For the full text of the amended Articles of Association, please refer to the HKEXnews website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.recbio.cn).

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. LIU Yong
Chairman

Jiangsu Province, the PRC, November 25, 2025

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.